Asset profile
CCS1477
Unknown / undisclosed
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2029-11.
Also in development:Acute Myeloid Leukemia · Phase 1/2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
121 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 120 same-indication; 34 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CCS1477: this drug | Phase 3 | — | CBP/p300 (bromodomain) | ||
| AUR107 | Phase 1 | Small molecule | CBP/p300 (bromodomain) | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Enasidenib | Approved | Small molecule | IDH2 | ||
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | ||
| Gilteritinib | Approved | Small molecule | FLT3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 |
…and 106 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
March 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.